Drugs / Smallpox vaccine
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05762523 | May → Jul 2019 | cowpox, monkeypox, smallpox, vaccinia | Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector" | Completed | No outcome recorded |
| Phase 1 | NCT00002261 | — | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00258947 | Sep 2005 → Dec 2006 | human infection by orthopoxvirus, smallpox | Sanofi | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Smallpox vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05762523 ↗ |
| Modality | Vaccine | “the Wyeth smallpox vaccine” NCT00002261 ↗ |
| Route | Other | “by the method of multiple puncture” NCT05762523 ↗ |